MedTrace Logo

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

NCT03881761 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-03-21

No results posted yet for this study

Summary

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

Conditions

  • B-Cell Lymphoma Stage I
  • Refractory
  • Relapsed

Interventions

BIOLOGICAL

CD19/CD20 bispecific CAR-T cells

collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg

Sponsors & Collaborators

  • Henan Hualong Biotechnology Company

    collaborator UNKNOWN

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Yongping Song, Dr. · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2021-01-31
Completion
2022-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881761 on ClinicalTrials.gov